A Pilot Study of MSCs Iufusion and Etanercept to Treat Ankylosing Spondylitis
Status:
Unknown status
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and clinical effect of mesenchymal stem
cells (MSCs) derived from human bone marrow at a dose of 1.0E+6 MSC/kg in subject for the
therapy of Ankylosing spondylitis (AS) and to compare the efficacy of MSCs and Etanercept to
treat this disease.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Collaborators:
Nanfang Hospital of Southern Medical University Second Affiliated Hospital of Guangzhou Medical University